Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815M in 2023, report finds

Taking stock of the drug industry, from the lab to the medicine chest

December 12, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Prices for 5 drugs were hiked without proof of new benefits, costing the U.S. $815M in 2023, report finds The nonprofit ICER said the price increases exceeded the medical consumer price index and occurred without evidence of new benefits from the drugs. By Ed Silverman STAT+ | Pfizer's blockbuster Ibrance slows tumor progression in another type of breast cancer New efficacy data from Pfizer could help broaden use of Ibrance, and cushion losses of market share to Kisqali, a similar drug from Novartis. By Matthew Herper STAT+ | Why Stoke Therapeutics' Dravet syndrome drug is worth watching The company is hoping that a planned clinical trial will set its treatment called zorevunersen apart from existing therapies. By Adam Feuerstein Adobe STAT+ | Arcellx won the battle of BCMA CAR-T therapies Data presented at the ASH meeting made a convincing case for a meaningful safety differentiation favoring anito-cel over Carvykti. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser